GSDMC and melanoma: Although many melanomas develop resistance to BRAF inhibitors,25 such as trametinib- and dabrafenib-resistant A375 melanoma cells (Supplementary Fig. 1g), DdBIC could induce pyroptosis in these resistant cells to an extent comparable to that in parental cells (Supplementary Fig. 1h), demonstrating that melanoma cells resistant to BRAF inhibitors remain sensitive to DdBIC-induced and GSDMC-dependent pyroptosis.